Tirzepatide is a dual GLP-1 and GIP receptor agonist, meaning it may act on two hormone pathways that influence appetite, satiety, and metabolic function. Lttl providers may consider compounded tirzepatide for eligible patients seeking weight management support. Plans start at $199/mo.
⚠ The compounded tirzepatide offered through Lttl is not the same as FDA-approved tirzepatide products and has not been reviewed or approved by the FDA for safety, effectiveness, or quality. Treatment appropriateness is determined solely by your licensed healthcare provider.
Comments
0 comments
Please sign in to leave a comment.